-
公开(公告)号：US20210188936A1
公开(公告)日：2021-06-24
申请号：US16606279
申请日：2018-04-20
申请人： YUHAN CORPORATION
发明人： Byung Hyun CHOI , In Hwan LIM , Jun Young PARK , Jin Hyoung LEE , Ki Hong KIM , Hae Yong JO , Jun Hwan KIM , Moo Young SONG , Jong Gyun KIM
IPC分类号： C07K14/605 , C07K14/50 , C12P21/02
摘要： A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
-
公开(公告)号：US20230212249A1
公开(公告)日：2023-07-06
申请号：US18068506
申请日：2022-12-19
申请人： YUHAN CORPORATION
发明人： Byung Hyun CHOI , In Hwan LIM , Jun Young PARK , Jin Hyoung LEE , Ki Hong KIM , Hae Yong JO , Jun Hwan KIM , Moo Young SONG , Jong Gyun KIM
CPC分类号： C07K14/605 , C12P21/02 , C07K14/50 , C07K19/00 , C07K16/46 , C12N5/00 , C07K2319/30 , C12N15/00
摘要： A method for producing a dual function protein includes a biologically active protein and an FGF21 mutant protein. The method allows stable production of a target protein by effectively preventing decomposition of the target protein, and thus has a high potential for commercial usage.
-
公开(公告)号：US20210221869A1
公开(公告)日：2021-07-22
申请号：US17256296
申请日：2019-07-24
发明人： Moo Young SONG , Taejin YOON , Jung-Sun LEE , Byung Hyun CHOI , In Hwan LIM , Man Sil PARK , Jin-Hyoung LEE , Hyoung Sig SEO , Hyeon Woo KANG , Sung Ho KIM , Eun Jig LEE , Jin Sook YOON , Cheol Ryong KU
IPC分类号： C07K14/72
摘要： Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.
-
公开(公告)号：US20180305428A1
公开(公告)日：2018-10-25
申请号：US15768616
申请日：2016-10-28
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61P1/16 , A61P3/04 , A61P3/10 , C07K2319/30
摘要： The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20240279296A1
公开(公告)日：2024-08-22
申请号：US18491616
申请日：2023-10-20
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
CPC分类号： C07K14/50 , A61P1/16 , A61P3/04 , A61P3/10 , A61K38/1825 , C07K2319/30
摘要： A fusion protein contains an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20220002367A1
公开(公告)日：2022-01-06
申请号：US17478600
申请日：2021-09-17
申请人： YUHAN CORPORATION
发明人： Jun Hwan KIM , Seyoung LIM , Minji SEO , Hyun Ho CHOI , Dohoon KIM , Mi Kyeong JU , Ju-Young PARK , Byung Hyun CHOI , Jun Kyung LEE , Jong Gyun KIM , Su Youn NAM
摘要： A fusion protein comprises an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
-
公开(公告)号：US20210087268A1
公开(公告)日：2021-03-25
申请号：US16970351
申请日：2019-02-28
申请人： YUHAN CORPORATION
发明人： Kwang-Hoon LEE , June Hyung LEE , Na Rae LEE , Eunjeong JEONG , Young Bong PARK , Nakho CHANG , Eun-Jung LEE , Ki Hong KIM , Sunghyun CHOI , Byung Hyun CHOI , Ju Young PARK , Moo Young SONG , Jong-Seo LEE , Kyu-Tae KIM , Bong-Kook KO
IPC分类号： C07K16/28
摘要： Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition.
The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
